Find Clinical Trial

An open label, multicentre, positron emission tomography (PET) imaging study using Zirconium-89 to investigate the biodistribution and tumour uptake of a PD-L1x4-1BB bispecific antibody (S095012) in patients with advanced solid tumours

← Back
Study Phase

Phase 1

Therapeutic Area


IndicationSolid tumors
Active substance/
Medical device


Active Substance CodeS095012
Protocol CodeCL1-95012-002
EudraCT Code2021‐001764‐20
NCT CodeNCT05638334

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.